CTKB
Cytek Biosciences IncKey Statistics
About Cytek Biosciences Inc
Cytek Biosciences Inc (CTKB) is a leading innovator in multi-parameter flow cytometry, delivering cutting-edge cell analysis solutions that are vital for advancements in the life sciences sector. Specializing in technologies that enhance cellular analyses, Cytek plays a significant role in research areas such as immunology, cancer diagnostics, and drug development. The company's commitment to innovation and exceptional customer service has established it as a key player in the biotechnology industry, effectively meeting the increasing demand for accurate and precise cell analysis tools. With a diverse product portfolio and a strong market presence, Cytek continues to push the boundaries of cell biology research, fostering breakthroughs that can transform healthcare outcomes.
Fundamentals
| Revenue (TTM) | $201.49M |
| Gross Profit (TTM) | $104.46M |
| EBITDA | $-32.80M |
| Operating Margin | -9.00% |
| Return on Equity | -18.00% |
| Return on Assets | -5.25% |
| Revenue/Share (TTM) | $1.58 |
| Book Value | $2.66 |
| Price-to-Book | 1.72 |
| Price-to-Sales (TTM) | 2.92 |
| EV/Revenue | 1.736 |
| EV/EBITDA | 222.69 |
| Quarterly Earnings Growth (YoY) | 73.50% |
| Quarterly Revenue Growth (YoY) | 8.10% |
| Shares Outstanding | $128.55M |
| Float | $96.92M |
| % Insiders | 8.41% |
| % Institutions | 66.32% |
Historical Volatility
Volatility is currently expanding